Granules India is primarily involved in the manufacturing and sale of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages (FDs).
The company’s consolidated net profit rose by 17.3% to Rs 152.03 crore, on a 2.4% increase in total revenue from operations to Rs 1,196.82 crore in Q4 FY25, compared to Q4 FY24.